Month: September 2026

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	17th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	342,142	281.75	281.5
Ordinary shares	Sales	70,097	281.75	281.75

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	18th September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Ipsen appoints Mariette Finet to its Board of Directors

PARIS, FRANCE, 18 SEPTEMBER 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Mariette Finet as a Director to its Board of Directors, effective immediately. Ms. Finet succeeds Ms. Michèle Ollier, who resigned from her position as Director on 1 August 2026.

A Doctor of Medicine and graduate of the University of Nancy, Ms. Finet brings more than 35 years of experience across the healthcare, pharmaceutical and life sciences sectors.

Ms. Finet began her career in the Medical Department of Laboratoires Beaufour in Paris, where she held positions in pharmaceutical asset analysis and conducted clinical research across several therapeutic areas, with a particular focus on gastroenterology. She subsequently joined Beaufour-Ipsen Pharma and later Ipsen, where she held positions in the Marketing Department.

Since 2007, Ms. Finet has served in scientific and medical advisory roles at Mayroy and Highrock S.àr.l., providing expertise in investment analysis and portfolio oversight, with a particular focus on pharmaceutical, MedTech and life sciences sectors. She also served on the boards of Lightinderm SAS and Kaerus Bioscience Ltd.

The Board of Directors has also appointed Ms. Finet to the Board Portfolio Committee, succeeding Ms. Ollier.

Ms. Finet’s appointment will be submitted for ratification at the next Annual Shareholders’ Meeting. Subject to ratification, she will serve for the remainder of Ms. Ollier’s term, which expires at the Annual Shareholders’ Meeting convened to approve the financial statements for the year ending 31 December 2026.

Following this appointment, Ipsen’s Board of Directors continues to comprise 14 directors, with balanced representation of seven women and seven men¹. The Board includes four independent directors and two employee representatives.

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen Contacts
Investors
Henry Wheeler	henry.wheeler@ipsen.com	+33 7 66 47 11 49
Khalid Deojee	khalid.deojee@ipsen.com	+33 6 66 01 95 26
Media
Sally Bain	sally.bain@ipsen.com	+1 857 320 0517
Anne Liontas	anne.liontas.ext@ipsen.com	+33 7 67 34 72 96

Disclaimers and/or forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

---

1 Representing 42%, with directors representing employees not taken into account in this calculation, pursuant to article L. 225-18-1 of the French Code of Commerce

Attachment

• EN_PR_BOD_Announcement_Mariette_FINET

Aktsiaselts Infortar’s subsidiary, AS Tallink Grupp, announced today that the maturity of its loan agreement has been extended by two years. The announcement is available at this link.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Luotea Plc
Stock exchange release
18 September at 10:00 a.m.

Composition of Luotea Plc’s Shareholders’ Nomination Board

The members of the Shareholders’ Nomination Board of Luotea Plc have been appointed.

The Company’s three largest shareholders are each entitled to appoint one member to the Nomination Board.

The shareholders entitled to appoint a representative to the Nomination Board shall be determined on the basis of the shareholders’ register maintained by Euroclear Finland Ltd on 1 September 2026 and the principles defined in the Charter of the Nomination Board. In accordance with the Charter of the Nomination Board, a group of shareholders may agree on the appointment of a joint representative to the Nomination Board.

The appointment of a joint representative has been agreed upon by the Evald and Hilda Nissi Foundation and Heikki Bergholm (shareholder group Evald and Hilda Nissi Foundation and Heikki Bergholm) and the shareholder group consisting of Chemec Oy, CH-Polymers Oy, Eeva Maijala, Maijala Investment Oy, Juhani Maijala, Juuso Maijala, Miikka Maijala, Mikko Maijala, Roope Maijala and Tuula Maijala (shareholder group Maijalat).

The following representatives of the Company’s three largest shareholder have been appointed to Luotea’s Shareholders’ Nomination Board:

• Heikki Bergholm, shareholder group Evald and Hilda Nissi Foundation and Heikki Bergholm (11.49% of shares and votes)
• Miikka Maijala, shareholder group Maijalat (9.42% of shares and votes)
• Vesa Ollikainen, Nordea Nordic Small Cap Fund (5.19% of shares and votes).

Johan Mild, Chairman of the Board of Directors of Luotea, is the fourth member of the Nomination Board. The Chairman of the Nomination Board is Miikka Maijala.

The Nomination Board prepares and presents to the Annual General Meeting and, if necessary, to the Extraordinary General Meeting proposals on the composition of the Board of Directors and the remuneration of its members.

LUOTEA PLC

Heikki Eskola
General Counsel

Further information:
Heikki Eskola, +358 50 586 5907, heikki.eskola@luotea.com

Distribution:
Nasdaq Helsinki
Main media
www.luotea.com

Luotea is a pioneer in facility services, offering comprehensive lifecycle solutions for buildings. We combine energy efficiency with innovative thinking to maximise property value and ensure the best conditions for every user. Our services range from advanced property maintenance, building technology and consultancy to professional cleaning and support. We grow sustainably and profitably, mindful of our impact on buildings, the environment and society. Leading the way, we drive our industry forward and shape a better tomorrow. For us, success is measured in trust – the trust our people, clients and owners have in us.

Luotea operates in Finland and Sweden, with 2025 net sales EUR 346 million and a workforce of approximately 5,000. Luotea is publicly listed on Nasdaq Helsinki

WUHU, China, Sept. 18, 2026 (GLOBE NEWSWIRE) — LEPAS, Chery Auto’s Premium NEV brand, will host its inaugural LEPAS Global Elegant Lifestyle Week this October during the 2026 Chery International User Summit. Bringing together global users, partners and cross-industry guests, the event will explore new possibilities for mobility and everyday life in the new energy era — extending elegance beyond the car to the way people connect with mobility and lifestyle.

Ahead of the event, LEPAS has stepped into cultural and lifestyle settings worldwide this summer — from historic cinemas in Europe and equestrian events in Southeast Asia to fashion gatherings in South Africa and art spaces in London. Through these engagements, LEPAS is exploring how “elegant mobility” can connect with diverse cultures and lifestyles.

One Vision of Elegance, Expressed Across Cultures

Across these settings, LEPAS moves beyond its role as a means of transport to become part of local aesthetic and cultural experiences: at a Malaysian equestrian event, sharing the field with young riders; at the Transilvania International Film Festival, celebrating originality with the creative community; at the Venice International Film Festival, joining filmmakers from around the world; and at London Design Festival, exploring the meaning of elegance with designers. Each offers a distinct expression of an elegant lifestyle shaped by its cultural context.

[LEPAS x Malaysian Prime Minister Cup Equestrian Competition]

This reflects LEPAS’s exploration of elegance as a value that can be perceived and experienced. Through three core pillars — Leopard Aesthetics, Elegant Technology and Exquisite Space — LEPAS maintains a consistent expression across cultures: design encourages self-expression, technology supports a composed experience, and space accommodates everyday life. Bringing these values into real-life settings makes LEPAS’s approach to elegance tangible for global customers.

In the Name of Elegance, Across Global Markets

For LEPAS, globalization means maintaining consistent brand values while understanding local cultures, responding to users’ needs, and building trust through sustained engagement.

In South Africa, LEPAS began connecting with communities before its products entered the market. Through sporting events, fashion shows, cultural gatherings and community initiatives, the brand has made its idea of elegance more tangible while building a local presence and connection.

[LEPAS x BLACK COFFEE Foundation Children’s Welfare Home Initiative]

From cultural engagement to market development, LEPAS builds awareness of elegance through lifestyle experiences, enters markets through brand and product launches, and supports elegant mobility through services. Together, these efforts make elegant living relevant across markets.

From individual events to citywide engagement, and from the car to everyday life, LEPAS is gradually expanding from an automotive brand into a lifestyle brand. Beyond how people move, it explores how mobility can become part of everyday life, with technology working in the background and elegance taking center stage.

This October, LEPAS Global Elegant Lifestyle Week will bring these explorations together, further connecting global users, partners and cross-industry guests through mobility and lifestyle.

About LEPAS

LEPAS is Chery Auto’s Premium NEV brand, dedicated to creating elegant mobility experiences for users worldwide. Committed to becoming the Preferred Brand for Elegant Mobility Life, LEPAS brings together Leopard Aesthetics, Elegant Technology, and Exquisite Space – transforming elegance into a driving experience you can see, feel, and trust. Supported by a growing global dealer network of more than 500 sales and service outlets, LEPAS is expanding its international footprint through localized operations, delivering products and experiences tailored to users across global markets.

Media Contact
Company Name: LEPAS International
Contact Person: Vincy wang
E-mail: wangxi23@mychery.com
Company Official Website: https://lepasinternational.com/

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/1514ee5c-9846-422e-be10-02c1073679dd

https://www.globenewswire.com/NewsRoom/AttachmentNg/6bf0bc46-2102-4969-88fa-3da013cd3958

https://www.globenewswire.com/NewsRoom/AttachmentNg/9192c0de-c18a-41bf-b5c7-50600a35f905

CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) — Jura Energy Corporation (“Jura” or the “Company”) provides clarification regarding a news article published by a Pakistani newspaper, Dawn, on September 13, 2026, which reported the possible revocation of petroleum rights held by the Company’s subsidiaries, Spud Energy Pty Limited (“SEPL”) and Frontier Holdings Limited (“FHL”), in Pakistan.

According to the media report, the Petroleum Division of the Government of Pakistan has reportedly sought the advice of Pakistan’s Economic Coordination Committee (“ECC”), a cabinet-level decision-taking body, regarding possible courses of action in connection with the March 2025 transfer of a 73% shareholding in Jura by Phoenix Exploration (“Phoenix”) to IDL Investments Limited (“IDL”) (the “Share Transfer”).

The article reports two options to be under consideration by the Petroleum Division: (i) revocation of the petroleum rights held by FHL and SEPL; or (ii) issuance of a warning to the Company, followed by retrospective regularisation of the share transfer.

Company’s Position

In July 2025, Jura received a Show Cause Notice from the Petroleum Division in relation to the Share Transfer. In Jura’s response, SEPL and FHL explained the reasons why the Share Transfer did not require prior consent of the Government under the applicable Pakistan Petroleum (Exploration and Production) Rules, 1986 and 2001 (the “Rules”). Jura’s position was supported by an independent legal opinion from a renowned Pakistani lawyer.

In light of the matters reported in the media, Jura has written to the regulatory authorities to seek clarification regarding the matters referred to in the article, including the reported courses of action under consideration by the Petroleum Division.

Jura will continue to engage constructively with the relevant authorities and will assess any response or further information received in relation to the matter. The Company believes it has been in full compliance with applicable laws, regulations and contractual obligations throughout and is committed to remaining so.

No Revocation of Petroleum Rights has been notified

Jura emphasizes that the media report describes possible courses of action reportedly under consideration by the relevant authorities and does not, in itself, constitute a confirmed decision to revoke the Company’s petroleum rights. In fact, Jura has had no communication from the regulatory authorities on this matter since it last responded to a query in June 2026. The press article may therefore not accurately reflect the situation.

The Company is not aware of any confirmed decision revoking the petroleum rights held by FHL or SEPL and has a number of legal and other avenues open to it if such an unusual decision were to be taken. Jura will continue to monitor developments and provide further disclosure as and when required by applicable securities laws and regulations.

About Jura Energy Corporation

Jura is an international energy company engaged in the exploration, development and production of petroleum and natural gas properties in Pakistan. Jura is based in Calgary, Alberta, and listed on the TSX-V trading under the symbol JEC. Jura conducts its business in Pakistan through its subsidiaries, Frontier Holdings Limited and Spud Energy Pty Limited.

Forward Looking Advisory

This press release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws. The words “will”, “continue”, “believes”, “may”, and similar expressions are used to identify forward looking information. Specific forward-looking statements in this press release include information regarding the Company’s future engagement with the relevant authorities and possible outcomes from matters under consideration by the relevant authorities.

The forward-looking statements contained in this press release are based on management’s beliefs, estimates and opinions on the date the statements are made in light of management’s experience, current conditions and expected future development in the areas in which Jura is currently active and other factors management believes are appropriate in the circumstances. Jura undertakes no obligation to update publicly or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise, unless required by applicable law

Readers are cautioned not to place undue reliance on forward-looking information. By their nature, forward-looking statements are subject to numerous assumptions, risks and uncertainties that contribute to the possibility that the predicted outcome will not occur, including some of which are beyond Jura’s control. These assumptions and risks include, but are not limited to: uncertainties relating to the determinations of the ECC regarding possible courses of action in connection with the Share Transfer, the risk of possible revocation of petroleum rights and the legal and other avenues available to the Company in case of possible revocation of petroleum rights. There can be no assurance that forward-looking statements will prove to be accurate as actual results and future events could vary or differ materially from those anticipated in such statements. See Jura’s Management’s Discussion and Analysis for the year ended December 31, 2025, available on SEDAR+ at www.sedarplus.ca, for further description of the risks and uncertainties associated with Jura’s business.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Stephen Smith, Chairman, Jura Energy Corporation        

T: +44 7834 834 976
E-Mail: info@juraenergy.com
Website: www.juraenergy.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.